Primo Nutraceuticals Inc.
BUGVFOTCHealthcare
$0.00
$-0.00(-24.29%)
Market Cap$26
P/E Ratio—
52W High$0.000001
52W Low$0.000001
Primo Nutraceuticals Inc. (BUGVF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · BUGVF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2019-07 |
|---|---|
| Revenue | |
| Revenue | $0.00B |
| Cost of Revenue | $0.00B |
| Gross Profit | $0.00B |
| Gross Margin %(computed) | — |
| Operating Expenses | |
| R&D Expenses | $0.00B |
| G&A Expenses | $0.00B |
| Total Operating Expenses | $0.00B |
| Operating Income | ($0.00B) |
| Operating Margin %(computed) | — |
| Interest Income | $0.00B |
| Interest Expense | $0.00B |
| Income Before Tax | ($0.00B) |
| Income Tax Expense | ($0.00B) |
| Net Income | ($0.00B) |
| Net Margin %(computed) | — |
| Per Share & EBITDA | |
| EPS (Basic) | $-0.88 |
| Wtd Avg Shares | 0.00B |
| EBITDA | ($0.00B) |
| EBITDA Margin %(computed) | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · CAD · B
Explore more Primo Nutraceuticals Inc. data
About Primo Nutraceuticals Inc. (BUGVF) Income Statement
Primo Nutraceuticals Inc. (BUGVF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2019, BUGVF reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.00B) — a net profit margin of —.
Frequently asked questions
BUGVF · 4 questionsPrimo Nutraceuticals Inc. (BUGVF) reported revenue of $0.00B for 2019, down —% year-over-year.
BUGVF revenueBUGVF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09